SPOTLIGHT: Maxygen closes Denmark facility

Maxygen is shutting down its Denmark facility--which has largely focused on preclinical activities--and is adding 25 staffers to its Redwood City headquarters as it restructures. Release

Suggested Articles

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.